Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types.
about
Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial.Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y Radioembolization.Impact of respiratory motion and acquisition settings on SPECT liver dosimetry for radioembolization.Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).
P2860
Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Fusion dual-tracer SPECT-based ...... de range of tumour cell types.
@ast
Fusion dual-tracer SPECT-based ...... de range of tumour cell types.
@en
type
label
Fusion dual-tracer SPECT-based ...... de range of tumour cell types.
@ast
Fusion dual-tracer SPECT-based ...... de range of tumour cell types.
@en
prefLabel
Fusion dual-tracer SPECT-based ...... de range of tumour cell types.
@ast
Fusion dual-tracer SPECT-based ...... de range of tumour cell types.
@en
P2093
P2860
P1476
Fusion dual-tracer SPECT-based ...... de range of tumour cell types.
@en
P2093
Andrei H Iagaru
Arjun Banerjee
Daniel Y Sze
Erik S Mittra
John D Louie
Marnix G E H Lam
Michael L Goris
P2860
P2888
P304
P356
10.1007/S00259-015-3048-Z
P577
2015-04-28T00:00:00Z